Two different paths, two different timelines
For people living with PTSD, the past several years have produced two of the most promising new directions in psychiatric care since the SSRIs arrived in the late 1980s. Ketamine and MDMA-assisted therapy both showed strong early signals. Both were covered widely in the press. Both raised hope that something could finally help the patients SSRIs had not.
The two are not on the same regulatory footing today, and that distinction matters more than any other detail in this comparison. Ketamine is a legally available medication that clinics like ours have been delivering for years for treatment-resistant depression and, off-label, for chronic PTSD. MDMA-assisted therapy is a research protocol. It is not approved, it is not legally available outside clinical trials, and after the FDA's August 2024 decision it will not be available in routine care any time soon.
This article walks through what the MDMA-assisted therapy trials actually showed, what happened at the FDA, how the two approaches compare on mechanism and structure, and what is realistically available to a person with PTSD who needs help now. Music City Ketamine does not offer MDMA-assisted therapy. The comparison here is for educational context only.
What MAPP1 and MAPP2 actually showed
The case for MDMA-assisted therapy was built on two phase 3 randomized controlled trials run by MAPS Public Benefit Corporation, later renamed Lykos Therapeutics. Both were published in Nature Medicine.
The first trial, often called MAPP1, was published by Mitchell and colleagues in 2021 in Nature Medicine. It enrolled 90 participants with severe PTSD and randomized them to either three sessions of MDMA paired with manualized therapy or three sessions of inactive placebo paired with the same therapy. The MDMA group showed significantly greater reductions in Clinician-Administered PTSD Scale scores than the placebo-with-therapy group, with a large effect size. Most participants in the MDMA arm no longer met diagnostic criteria for PTSD by the end of the protocol.
The confirmatory trial, MAPP2, was published by Mitchell and colleagues in 2023 in Nature Medicine. It replicated the MAPP1 findings in a more demographically diverse sample of 104 participants, again showing significantly greater PTSD symptom reduction in the MDMA-with-therapy group than in the placebo-with-therapy group. Together, the two trials made up a strong-looking package for FDA submission.
Both trials paired the medication with intensive psychotherapy. Each MDMA dosing session ran roughly eight hours and was supervised by two trained therapists. The dosing sessions were sandwiched between multiple preparatory sessions and integration sessions, which together represented dozens of clinical hours per participant. The protocol is not a pill. It is a structured program of medication-assisted psychotherapy.
What happened with the FDA in August 2024
Despite the trial results, the FDA declined to approve midomafetamine (MDMA) capsules for PTSD. In August 2024 the agency issued a Complete Response Letter to Lykos Therapeutics, requesting additional clinical data before any approval could be considered. An FDA advisory committee earlier that summer had voted against approval, citing concerns about trial design, the difficulty of blinding participants to MDMA, allegations of protocol violations at trial sites, and questions about whether the therapy component itself could be evaluated as a regulated product.
What this means in practical terms is that MDMA-assisted therapy is not a legal treatment in the United States. It is not available in Tennessee. It is not available through compassionate use in any reliable way. MDMA itself remains a Schedule I controlled substance. The path to a new FDA filing requires Lykos to run additional trials, which takes years.
Some patients with the means to travel may pursue ketamine through legal clinical channels in the United States or look into research-trial enrollment for other compounds. Music City Ketamine cannot enroll patients in MDMA research, and we will not refer patients to anything operating outside the law.
Mechanism: NMDA antagonist vs serotonin releaser
The two medications work very differently in the brain, and the differences help explain why they produce such different session experiences.
Ketamine is an NMDA glutamate-receptor antagonist. By blocking NMDA receptors and triggering a downstream surge in synaptic plasticity, ketamine appears to open a window in which the brain can form new neural connections more readily than usual. It does not produce a sustained empathogenic state. The infusion experience is dissociative and time-limited, and most of the therapeutic effect appears to come from the neuroplastic changes that follow.
MDMA is a substituted amphetamine that triggers release of serotonin, dopamine, and norepinephrine, while also raising oxytocin and reducing amygdala activity. Patients describe the experience as one of softened defenses, increased trust, and reduced fear when revisiting traumatic memories. The hypothesis behind MDMA-assisted therapy is that this state lets a patient process trauma in a single sitting in ways that ordinary trauma-focused therapy cannot.
These are not interchangeable mechanisms. Ketamine is a brief biochemical reset that may unlock change. MDMA, in the trial protocols, is a long emotional opening that is supposed to be filled with therapy. Neither is a cure-all, and neither works for every patient.
Session structure: 40 minutes vs 8 hours
The day-of experience is one of the largest practical differences.
- IV ketamine: A standard infusion at our clinic runs about 40 minutes, with a short recovery period before discharge. A typical induction series is six sessions over two to three weeks, with maintenance sessions afterward as needed. You need a driver. Most patients return to normal activities the next day.
- MDMA-assisted therapy (in MAPP1/MAPP2): Each dosing session was 6 to 8 hours with two therapists in the room throughout. Three dosing sessions were spaced about a month apart. Around each dosing session were three preparatory and three integration psychotherapy sessions. The full protocol represented many dozens of clinical hours.
That difference is not just convenience. It is cost, time off work, access to trained therapists, and emotional bandwidth. Even if MDMA-assisted therapy had been approved in 2024, the structural cost of delivering it would have made widespread access slow and uneven for years.
What ketamine offers PTSD patients today
Ketamine is FDA-approved as an anesthetic; its use for PTSD is off-label. That said, the evidence base for ketamine in PTSD has grown steadily. Feder and colleagues, writing in the American Journal of Psychiatry in 2021, reported a randomized controlled trial of repeated IV ketamine versus midazolam control in chronic PTSD. The ketamine group showed significant and rapid reductions in PTSD symptoms, with a meaningful proportion of participants meeting response criteria. Earlier work by the same research group had shown rapid PTSD symptom reduction after a single ketamine infusion.
For people who have lived with PTSD for years, who have already cycled through SSRIs and trauma-focused therapy without enough relief, what ketamine offers is concrete: a treatment that is legally available, that has direct trial data in PTSD, and that can begin within weeks rather than years. We see this most often in veterans and first responders, populations carrying high baseline trauma loads with limited time and patience for treatments that may or may not be approved someday.
Ketamine is not a substitute for trauma-focused therapy. Most patients who do well on ketamine pair their infusions with a therapist who knows how to work with the neuroplastic window. Our deeper write-up on ketamine for PTSD covers protocols, evidence, and what to expect in detail. The PTSD program page outlines who is and is not a candidate.
Honest expectations
We try to be careful with how we talk about both treatments, because PTSD is a condition that has produced more overpromised cures than almost any other in psychiatry.
- Ketamine does not work for everyone. Response rates in PTSD trials are meaningful but not universal. Some patients see significant relief; others see partial improvement; a minority do not respond. Research suggests outcomes are best when ketamine is paired with skilled trauma therapy and a thoughtful maintenance plan.
- MDMA-assisted therapy has not been shown to be safe and effective to the FDA's standard. The MAPP1 and MAPP2 results were strong, but the agency identified questions that need new data. Treating an unapproved protocol as a known good is not honest.
- Off-label use is not the same as unproven use. Ketamine has thousands of patients in published trials and decades of clinical anesthesia experience. Off-label means the FDA has not formally approved this indication; it does not mean the evidence is absent.
- Cost is a real factor. IV ketamine in our clinic is a self-pay treatment at $475 per session, with multiple sessions in a typical induction series. Whatever the future cost of MDMA-assisted therapy turns out to be, the dozens of clinical hours it requires will make it expensive too.
Watching the next FDA filing
Lykos has stated publicly that it intends to continue its work toward an MDMA-assisted therapy approval. New trials, better blinding, and stronger trial-site oversight will all be required. A second NDA, if it comes, is years away.
In the meantime the comparison is not really ketamine versus MDMA. It is ketamine, available now, against a treatment that may or may not be approved at some future date. For a patient whose life is being narrowed by PTSD today, that is a different calculation than a head-to-head efficacy comparison would suggest.
What to expect at Music City Ketamine
If you are considering ketamine for PTSD, we start with a thorough consultation. We review your diagnosis, your history with previous treatments, current medications, and what you are hoping to get out of treatment. We do not promise a cure. We do not promise that ketamine will work for you specifically. We do explain what the data shows, what we have seen in our own patients, and what an honest course of treatment looks like.
Each infusion is supervised by Marla Peterson, CRNA, who oversees every infusion and provides anesthesia-level monitoring. Continuous pulse oximetry, blood pressure tracking, and heart rate tracking are standard. The clinical environment is private and quiet, with comfortable recliners and our therapy dogs Walter White and Wilma nearby. You will need a driver.
Never start, stop, or change any psychiatric medication on your own. Always discuss medication adjustments with your prescribing provider before and during a course of ketamine therapy.